BROSHY ERAN
SEC Form 4 insider trading activity
BROSHY ERAN has filed 4 SEC Form 4 filings (9 transaction rows) across 2 companies, including CERT, TBPH, with disclosures dating back to 2025. 4 of those filings fall inside the rolling window. Most recent filing: May 15, 2026.
On the most recent filing, BROSHY ERAN is listed as Director at Theravance Biopharma, Inc. Inside the rolling window, BROSHY ERAN reported no open-market purchases and 2 open-market sales totaling $1.9M in TBPH. The largest disclosed transaction in the window is a sale of 74,500 TBPH shares on Nov 11, 2025, worth $1.4M.
Companies traded
Other insiders at CERT
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$1.9M
reported sales (SEC code S)
Companies
2
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has BROSHY ERAN made?
BROSHY ERAN has filed 4 SEC Form 4 filings (9 transaction rows) across 2 companies, including CERT, TBPH since 2025.
Which companies does BROSHY ERAN trade?
BROSHY ERAN has filed SEC Form 4 disclosures for 2 companies, including CERT, TBPH.
When was BROSHY ERAN's most recent SEC Form 4 filing?
BROSHY ERAN's most recent SEC Form 4 filing on Tracefour is dated May 15, 2026.
What is BROSHY ERAN's total buy and sell value in the current window?
Inside the rolling retention window, BROSHY ERAN bought $0 and sold $1.9M based on SEC Form 4 filings.
What was BROSHY ERAN's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 74,500 TBPH shares on 2025-11-11, worth $1.4M, per SEC Form 4 filings.